Analyzing the clinical outcomes of switching from cyclosporine to tacrolimus in pediatric hematopoietic stem cell transplantation

被引:3
作者
Yalcin, Koray [1 ]
Celen, Suna [1 ]
Zhumatayev, Suleimen [1 ]
Daloglu, Hayriye [2 ]
Pashayev, Dayanat [1 ]
Ozturkmen, Seda [2 ]
Uygun, Vedat [2 ]
Karasu, Gulsun [1 ]
Yesilipek, Akif [1 ,2 ]
机构
[1] Med Pk Goztepe Hosp, Pediat Bone Marrow Transplantat Unit, Istanbul, Turkey
[2] Med Pk Goztepe Hosp, Pediat Bone Marrow Transplantat Unit, Antalya, Turkey
关键词
cyclosporine; pediatric hematopoietic stem cell; tacrolimus; VERSUS-HOST-DISEASE; MARROW-TRANSPLANTATION; CALCINEURIN INHIBITORS; COMPARING METHOTREXATE; GVHD PROPHYLAXIS; PHASE-III; FK506; CHILDREN; PREVENTION; CONVERSION;
D O I
10.1111/ctr.14328
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective The selection of graft-vs. -host disease (GvHD) prophylaxis is vital for the success of hematopoetic stem cell transplantation (HSCT), and calcineurin inhibitors (CNI) have been used for decades as the backbone of GvHD prophylaxis. The aim of this study is to analyze the results of switching cyclosporine (CSA) to tacrolimus because of acute GvHD, engraftment syndrome (ES), persistent low level of CSA, or various CSA-associated adverse events in the first 100 days of pediatric HSCT. Materials and Methods This is a retrospective analysis of 192 patients who underwent allogeneic hematopoietic stem cell transplantation at Medicalpark Goztepe and Antalya Hospitals between April 2014 and May 2019 had therapy switched from CSA to tacrolimus-based immunosuppression within 100 days of transplant. Results The reasons for conversion to tacrolimus were low level of CSA (n = 70), aGvHD (n = 63), CSA-associated neurotoxicity (n = 15), CSA-associated nephrotoxicity (n = 10), hypertension (n = 10), allergic reactions (n = 9), ES (n = 7), CSA-associated hepatotoxicity (n = 5), and vomiting (n = 3). The median day after transplant for conversion to tacrolimus for all patients was day 20 (range 0-100 days). Response rates to conversion were 38% for GvHD, 86% for neurotoxicity, 50% for nephrotoxicity, 60% for hepatotoxicity, 80% for hypertension, 66% for vomiting, and 57% for ES. Twenty-nine patients (15%) experienced tacrolimus-associated toxicities after therapy conversion to tacrolimus. Neurotoxicity emerged as posterior reversible encephalopathy syndrome (PRES), which was the most common toxicity observed after conversion (18/29 patients). Conclusion Our data support the quick conversion to tacrolimus in the condition of persistent low CSA levels with acceptable efficacy and safety. Although both drugs are CNI and share a very similar mechanism of action, the conversion could be preferred especially in specific organ toxicities with special attention for neurotoxicity after conversion.
引用
收藏
页数:8
相关论文
共 50 条
[41]   Incidence, risk factors, and clinical outcomes of cataracts following hematopoietic stem cell transplantation [J].
Najima, Yuho ;
Kakihana, Kazuhiko ;
Ohashi, Kazuteru ;
Yamamoto, Narumichi ;
Kobayashi, Takeshi ;
Yamashita, Takuya ;
Sakamaki, Hisashi ;
Akiyama, Hideki .
AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (06) :508-510
[42]   Pilot Study of Parent Psychophysiologic Outcomes in Pediatric Hematopoietic Stem Cell Transplantation [J].
Ward, Jessica ;
Swanson, Barbara ;
Fogg, Louis ;
Rodgers, Cheryl .
CANCER NURSING, 2017, 40 (03) :E48-E57
[43]   Parent Psychological and Physical Health Outcomes in Pediatric Hematopoietic Stem Cell Transplantation [J].
Ward, Jessica ;
Fogg, Louis ;
Rodgers, Cheryl ;
Breitenstein, Susie ;
Kapoor, Neena ;
Swanson, Barbara A. .
CANCER NURSING, 2019, 42 (06) :448-457
[44]   Outcomes of hematopoietic stem cell transplantation in 813 pediatric patients with Fanconi anemia [J].
Lum, Su Han ;
Eikema, Dirk-Jan ;
Piepenbroek, Brian ;
Wynn, Robert F. ;
Samarasinghe, Sujith ;
Dalissier, Arnaud ;
Kalwak, Krysztof ;
Ayas, Mouhab ;
Hamladji, Rose-Marie ;
Yesilipek, Akif ;
Dalle, Jean-Hugues ;
Uckan-Cetinkaya, Duygu ;
Bierings, Marc ;
Kupesiz, Alphan ;
Halahleh, Khalid ;
Skorobogatova, Elena ;
Ozturk, Gulyuz ;
Faraci, Maura ;
Renard, Cecile ;
Evans, Pamela ;
Corbacioglu, Selim ;
Locatelli, Franco ;
Dufour, Carlo ;
Risitano, Antonio ;
de Latour, Regis Peffault .
BLOOD, 2024, 144 (12) :1329-1342
[45]   Outcomes From Unrelated Donor Hematopoietic Stem Cell Transplantation [J].
Perez, Lia Elena .
CANCER CONTROL, 2011, 18 (04) :216-221
[46]   Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia [J].
Merli, Pietro ;
Algeri, Mattia ;
Del Bufalo, Francesca ;
Locatelli, Franco .
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (02) :94-105
[47]   Continuous versus intermittent tacrolimus for graft-versus-host disease prophylaxis in pediatric hematopoietic stem cell transplantation patients (Tic Tac) [J].
Asleson, Demi ;
Carr, Roxane ;
Rozmus, Jacob ;
Kendrick, Jennifer .
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2025,
[48]   Clinical Controversy in Transplantation: Tacrolimus Versus Cyclosporine in Statin Drug Interactions [J].
Migliozzi, Daniel R. ;
Asal, Nicole J. .
ANNALS OF PHARMACOTHERAPY, 2020, 54 (02) :171-177
[49]   Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation [J].
Majhail, Navneet S. ;
Challa, Tejo R. ;
Mulrooney, Daniel A. ;
Baker, K. Scott ;
Burns, Linda J. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (09) :1100-1107
[50]   Population pharmacokinetics of cyclosporine in Chinese children receiving hematopoietic stem cell transplantation [J].
Li, Tai-feng ;
Hu, Lei ;
Ma, Xiao-lu ;
Huang, Lin ;
Liu, Xue-mei ;
Luo, Xing-xian ;
Feng, Wan-yu ;
Wu, Chun-fu .
ACTA PHARMACOLOGICA SINICA, 2019, 40 (12) :1603-1610